Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.13
NYSE:LCI's Cash-to-Debt is ranked lower than
89% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NYSE:LCI: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:LCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.09 Max: 228.13
Current: 0.13
0
228.13
Equity-to-Asset 0.36
NYSE:LCI's Equity-to-Asset is ranked lower than
85% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:LCI: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:LCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.7 Max: 0.92
Current: 0.36
-1.05
0.92
Debt-to-Equity 1.55
NYSE:LCI's Debt-to-Equity is ranked lower than
92% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NYSE:LCI: 1.55 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:LCI' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.43  Med: 0.11 Max: 38.67
Current: 1.55
-6.43
38.67
Debt-to-EBITDA 4.35
NYSE:LCI's Debt-to-EBITDA is ranked lower than
84% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NYSE:LCI: 4.35 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:LCI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -289.65  Med: 0.47 Max: 6.57
Current: 4.35
-289.65
6.57
Interest Coverage 1.69
NYSE:LCI's Interest Coverage is ranked lower than
95% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. NYSE:LCI: 1.69 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:LCI' s Interest Coverage Range Over the Past 10 Years
Min: 0.97  Med: 40.35 Max: 1094.14
Current: 1.69
0.97
1094.14
Piotroski F-Score: 6
Altman Z-Score: 1.70
Beneish M-Score: -2.40
WACC vs ROIC
5.85%
7.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 23.52
NYSE:LCI's Operating Margin % is ranked higher than
68% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NYSE:LCI: 23.52 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:LCI' s Operating Margin % Range Over the Past 10 Years
Min: -7.5  Med: 11.42 Max: 55.67
Current: 23.52
-7.5
55.67
Net Margin % 6.71
NYSE:LCI's Net Margin % is ranked lower than
71% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NYSE:LCI: 6.71 )
Ranked among companies with meaningful Net Margin % only.
NYSE:LCI' s Net Margin % Range Over the Past 10 Years
Min: -3.2  Med: 5.87 Max: 36.85
Current: 6.71
-3.2
36.85
ROE % 7.64
NYSE:LCI's ROE % is ranked lower than
68% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NYSE:LCI: 7.64 )
Ranked among companies with meaningful ROE % only.
NYSE:LCI' s ROE % Range Over the Past 10 Years
Min: -3.32  Med: 8.85 Max: 39.56
Current: 7.64
-3.32
39.56
ROA % 2.53
NYSE:LCI's ROA % is ranked lower than
67% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NYSE:LCI: 2.53 )
Ranked among companies with meaningful ROA % only.
NYSE:LCI' s ROA % Range Over the Past 10 Years
Min: -2.12  Med: 4.71 Max: 35.21
Current: 2.53
-2.12
35.21
ROC (Joel Greenblatt) % 30.72
NYSE:LCI's ROC (Joel Greenblatt) % is ranked higher than
59% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NYSE:LCI: 30.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:LCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.63  Med: 27.67 Max: 133.12
Current: 30.72
-11.63
133.12
3-Year Revenue Growth Rate 30.30
NYSE:LCI's 3-Year Revenue Growth Rate is ranked higher than
91% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NYSE:LCI: 30.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:LCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.8  Med: 14 Max: 91.7
Current: 30.3
-20.8
91.7
3-Year EBITDA Growth Rate 13.00
NYSE:LCI's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NYSE:LCI: 13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:LCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -92  Med: 25.7 Max: 153.4
Current: 13
-92
153.4
GuruFocus has detected 5 Warning Signs with Lannett Co Inc NYSE:LCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:LCI's 30-Y Financials

Financials (Next Earnings Date: 2018-02-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

LCI Guru Trades in Q4 2016

Joel Greenblatt 618,606 sh (+120.79%)
Ronald Muhlenkamp 504,379 sh (+86.17%)
Richard Snow 2,525,635 sh (+54.18%)
Ken Fisher Sold Out
Paul Tudor Jones 9,900 sh (-36.85%)
» More
Q1 2017

LCI Guru Trades in Q1 2017

Paul Tudor Jones 14,800 sh (+49.49%)
Richard Snow 3,093,435 sh (+22.48%)
Joel Greenblatt 695,498 sh (+12.43%)
Ronald Muhlenkamp 486,510 sh (-3.54%)
» More
Q2 2017

LCI Guru Trades in Q2 2017

Paul Tudor Jones 25,188 sh (+70.19%)
Richard Snow 3,152,240 sh (+1.90%)
Joel Greenblatt Sold Out
Ronald Muhlenkamp 486,060 sh (-0.09%)
» More
Q3 2017

LCI Guru Trades in Q3 2017

Chuck Royce 590 sh (New)
Richard Snow 3,435,152 sh (+8.97%)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 454,873 sh (-6.42%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2017-09-30 Reduce -6.42%0.2%$15.1 - $22.7 $ 23.9530%454,873
Ronald Muhlenkamp 2017-06-30 Reduce -0.09%$18.45 - $27.15 $ 23.9510%486,060
Joel Greenblatt 2017-06-30 Sold Out 0.2%$18.45 - $27.15 $ 23.9510%0
Joel Greenblatt 2017-03-31 Add 12.43%0.02%$18.8 - $23.55 $ 23.9512%695,498
Ronald Muhlenkamp 2017-03-31 Reduce -3.54%0.12%$18.8 - $23.55 $ 23.9512%486,510
Joel Greenblatt 2016-12-31 Add 120.79%0.1%$17.25 - $27.82 $ 23.954%618,606
Ronald Muhlenkamp 2016-12-31 Add 86.17%1.62%$17.25 - $27.82 $ 23.954%504,379
Ken Fisher 2016-12-31 Sold Out $17.25 - $27.82 $ 23.954%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSX:ACB, NAS:EGRX, SZSE:000597, NAS:AMPH, SHSE:600530, SZSE:300086, TSX:LEAF, NAS:HRTX, SHSE:603669, BOM:530549, TSE:4553, BOM:540222, TPE:1789, SHSE:603168, SZSE:300436, HKSE:02877, TPE:1707, SHSE:603998, TSX:APH, ADX:JULPHAR » details
Traded in other countries:LN5.Germany,
Headquarter Location:USA
Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Ratios

vs
industry
vs
history
PE Ratio 21.39
LCI's PE Ratio is ranked lower than
99.99% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. LCI: 21.39 )
Ranked among companies with meaningful PE Ratio only.
LCI' s PE Ratio Range Over the Past 10 Years
Min: 7.92  Med: 24.59 Max: 222.5
Current: 21.39
7.92
222.5
Forward PE Ratio 8.06
LCI's Forward PE Ratio is ranked higher than
89% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. LCI: 8.06 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.39
LCI's PE Ratio without NRI is ranked lower than
99.99% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. LCI: 21.39 )
Ranked among companies with meaningful PE Ratio without NRI only.
LCI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.92  Med: 24.59 Max: 222.5
Current: 21.39
7.92
222.5
Price-to-Owner-Earnings 17.17
LCI's Price-to-Owner-Earnings is ranked higher than
63% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. LCI: 17.17 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LCI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.44  Med: 18.81 Max: 834.91
Current: 17.17
4.44
834.91
PB Ratio 1.55
LCI's PB Ratio is ranked higher than
84% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. LCI: 1.55 )
Ranked among companies with meaningful PB Ratio only.
LCI' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.61 Max: 6.39
Current: 1.55
0.61
6.39
PS Ratio 1.43
LCI's PS Ratio is ranked higher than
81% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. LCI: 1.43 )
Ranked among companies with meaningful PS Ratio only.
LCI' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.37 Max: 7.1
Current: 1.43
0.48
7.1
Price-to-Free-Cash-Flow 12.02
LCI's Price-to-Free-Cash-Flow is ranked higher than
92% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. LCI: 12.02 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LCI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.22  Med: 19.12 Max: 213.77
Current: 12.02
3.22
213.77
Price-to-Operating-Cash-Flow 7.03
LCI's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. LCI: 7.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LCI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.89  Med: 14.57 Max: 288.5
Current: 7.03
2.89
288.5
EV-to-EBIT 11.16
LCI's EV-to-EBIT is ranked higher than
62% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. LCI: 11.16 )
Ranked among companies with meaningful EV-to-EBIT only.
LCI' s EV-to-EBIT Range Over the Past 10 Years
Min: -277  Med: 11.9 Max: 348.4
Current: 11.16
-277
348.4
EV-to-EBITDA 8.15
LCI's EV-to-EBITDA is ranked higher than
76% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. LCI: 8.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
LCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2304.2  Med: 10.7 Max: 681
Current: 8.15
-2304.2
681
EV-to-Revenue 2.67
LCI's EV-to-Revenue is ranked higher than
61% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. LCI: 2.67 )
Ranked among companies with meaningful EV-to-Revenue only.
LCI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 1.6 Max: 7.6
Current: 2.67
0.4
7.6
PEG Ratio 0.36
LCI's PEG Ratio is ranked lower than
99.99% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. LCI: 0.36 )
Ranked among companies with meaningful PEG Ratio only.
LCI' s PEG Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.39 Max: 196.47
Current: 0.36
0.07
196.47
Shiller PE Ratio 27.96
LCI's Shiller PE Ratio is ranked higher than
75% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. LCI: 27.96 )
Ranked among companies with meaningful Shiller PE Ratio only.
LCI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.32  Med: 75.3 Max: 1389
Current: 27.96
19.32
1389
Current Ratio 2.52
LCI's Current Ratio is ranked higher than
53% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. LCI: 2.52 )
Ranked among companies with meaningful Current Ratio only.
LCI' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.39 Max: 10.52
Current: 2.52
0.96
10.52
Quick Ratio 1.90
LCI's Quick Ratio is ranked higher than
54% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. LCI: 1.90 )
Ranked among companies with meaningful Quick Ratio only.
LCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.68 Max: 9.3
Current: 1.9
0.26
9.3
Days Inventory 135.34
LCI's Days Inventory is ranked lower than
58% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. LCI: 135.34 )
Ranked among companies with meaningful Days Inventory only.
LCI' s Days Inventory Range Over the Past 10 Years
Min: 68.82  Med: 115.5 Max: 165.34
Current: 135.34
68.82
165.34
Days Sales Outstanding 141.71
LCI's Days Sales Outstanding is ranked lower than
77% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. LCI: 141.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
LCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.9  Med: 108.89 Max: 171.98
Current: 141.71
78.9
171.98
Days Payable 52.89
LCI's Days Payable is ranked lower than
68% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. LCI: 52.89 )
Ranked among companies with meaningful Days Payable only.
LCI' s Days Payable Range Over the Past 10 Years
Min: 49.15  Med: 74.51 Max: 88.36
Current: 52.89
49.15
88.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.20
LCI's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. LCI: -1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37  Med: -5.5 Max: 26.7
Current: -1.2
-37
26.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.68
LCI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. LCI: 0.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LCI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.34 Max: 5.86
Current: 0.68
0.52
5.86
Price-to-Median-PS-Value 1.05
LCI's Price-to-Median-PS-Value is ranked higher than
74% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. LCI: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.2 Max: 8.14
Current: 1.05
0.5
8.14
Price-to-Peter-Lynch-Fair-Value 0.86
LCI's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. LCI: 0.86 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LCI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.19 Max: 15.96
Current: 0.86
0.36
15.96
Earnings Yield (Greenblatt) % 8.97
LCI's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. LCI: 8.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.9  Med: 5.7 Max: 20
Current: 8.97
-12.9
20
Forward Rate of Return (Yacktman) % 61.59
LCI's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. LCI: 61.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LCI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.5  Med: 4.3 Max: 129.6
Current: 61.59
-11.5
129.6

More Statistics

Revenue (TTM) (Mil) $626.74
EPS (TTM) $ 1.12
Beta1.86
Short Percentage of Float63.36%
52-Week Range $14.90 - 27.90
Shares Outstanding (Mil)37.67

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 706 690 691
EPS ($) 2.95 2.80 2.77
EPS without NRI ($) 2.95 2.80 2.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}